JP2025525406A - ピリド［４，３－ｄ］ピリミジン化合物 - Google Patents

ピリド［４，３－ｄ］ピリミジン化合物

Info

Publication number
JP2025525406A
JP2025525406A JP2024576355A JP2024576355A JP2025525406A JP 2025525406 A JP2025525406 A JP 2025525406A JP 2024576355 A JP2024576355 A JP 2024576355A JP 2024576355 A JP2024576355 A JP 2024576355A JP 2025525406 A JP2025525406 A JP 2025525406A
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
mmol
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024576355A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025525406A5 (enExample
Inventor
コ―ル ディーフォーリスト ジェイコブ
ナガタ アサコ
ポール プランケン サイモン
エリス シュパングラー ジリアン
チャニング サットン スコット
ハワード タトラック ジョン
Original Assignee
ファイザー・インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファイザー・インク filed Critical ファイザー・インク
Publication of JP2025525406A publication Critical patent/JP2025525406A/ja
Publication of JP2025525406A5 publication Critical patent/JP2025525406A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2024576355A 2022-07-05 2023-06-30 ピリド［４，３－ｄ］ピリミジン化合物 Pending JP2025525406A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202263358324P 2022-07-05 2022-07-05
US63/358,324 2022-07-05
US202263394338P 2022-08-02 2022-08-02
US63/394,338 2022-08-02
US202263414939P 2022-10-11 2022-10-11
US63/414,939 2022-10-11
US202363502931P 2023-05-18 2023-05-18
US63/502,931 2023-05-18
PCT/IB2023/056844 WO2024009191A1 (en) 2022-07-05 2023-06-30 Pyrido[4,3-d]pyrimidine compounds

Publications (2)

Publication Number Publication Date
JP2025525406A true JP2025525406A (ja) 2025-08-05
JP2025525406A5 JP2025525406A5 (enExample) 2025-10-03

Family

ID=87426656

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024576355A Pending JP2025525406A (ja) 2022-07-05 2023-06-30 ピリド［４，３－ｄ］ピリミジン化合物

Country Status (17)

Country Link
EP (1) EP4551296A1 (enExample)
JP (1) JP2025525406A (enExample)
KR (1) KR20250029954A (enExample)
CN (1) CN119585286A (enExample)
AU (1) AU2023302139A1 (enExample)
CA (1) CA3261000A1 (enExample)
CL (1) CL2024003699A1 (enExample)
CO (1) CO2024016875A2 (enExample)
CR (1) CR20240556A (enExample)
DO (1) DOP2024000275A (enExample)
IL (1) IL317957A (enExample)
MA (1) MA71388A (enExample)
MX (1) MX2024015001A (enExample)
PE (1) PE20250259A1 (enExample)
PY (1) PY2352053A (enExample)
TW (2) TWI869913B (enExample)
WO (1) WO2024009191A1 (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020020307A2 (pt) 2018-04-04 2021-01-12 Arvinas Operations, Inc. Moduladores de proteólise e métodos de uso associados
MD4051678T2 (en) 2019-10-28 2026-07-31 Merck Sharp & Dohme Llc Small molecule inhibitors of the KRAS G12C mutant
WO2021085653A1 (en) 2019-10-31 2021-05-06 Taiho Pharmaceutical Co., Ltd. 4-aminobut-2-enamide derivatives and salts thereof
EP4067343A4 (en) 2019-11-29 2024-01-03 Taiho Pharmaceutical Co., Ltd. NEW PHENOLIC COMPOUND OR SALT THEREOF
US12702658B2 (en) 2020-04-24 2026-08-11 Taiho Pharmaceutical Co., Ltd. Anticancer combination therapy with N-(1-acryloyl-azetidin-3-yl)-2-((1H-indazol-3-yl)amino)methyl)-1H-imidazole-5-carboxamide inhibitor of KRAS-G12C
WO2021215544A1 (en) 2020-04-24 2021-10-28 Taiho Pharmaceutical Co., Ltd. Kras g12d protein inhibitors
WO2022109487A1 (en) 2020-11-23 2022-05-27 Merck Sharp & Dohme Corp. Spirocyclic-substituted 6,7-dihydro-pyrano[2,3-d]pyrimidine inhibitors of kras g12c mutant
US20260200925A1 (en) * 2021-11-24 2026-07-16 Merck Sharp & Dohme Llc Small molecule inhibitors of kras mutated proteins
WO2023172737A1 (en) 2022-03-11 2023-09-14 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
AU2023320565A1 (en) 2022-08-05 2025-01-23 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
WO2024032703A1 (en) * 2022-08-11 2024-02-15 Beigene, Ltd. Heterocyclic compounds, compositions thereof, and methods of treatment therewith
AU2023321005A1 (en) * 2022-08-12 2025-03-20 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Tricyclic compounds and medical use thereof
TW202434606A (zh) * 2022-11-17 2024-09-01 大陸商江蘇恆瑞醫藥股份有限公司 稠合三環類化合物、其製備方法及其在醫藥上的應用
PE20260006A1 (es) 2023-01-26 2026-01-06 Arvinas Operations Inc Protacs degradadores de kras basados en cereblon y usos relacionados con los mismos
WO2024178304A1 (en) * 2023-02-24 2024-08-29 Alterome Therapeutics, Inc. Kras modulators
CN121487738A (zh) 2023-03-30 2026-02-06 锐新医药公司 诱导ras gtp水解的组合物和其用途
CR20250413A (es) * 2023-04-05 2025-11-06 Pfizer Compuestos de pirido[4,3–d]pirimidina
WO2024218686A1 (en) * 2023-04-20 2024-10-24 Pfizer Inc. Pyrido[4,3-d]pyrimidine compounds
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
CN121194980A (zh) * 2023-05-16 2025-12-23 和记黄埔医药（上海）有限公司 三环类化合物及其用途
EP4724445A1 (en) 2023-06-06 2026-04-15 Kumquat Biosciences Inc. Substituted heterocycles and uses thereof
EP4735451A1 (en) 2023-06-30 2026-05-06 Kumquat Biosciences Inc. Substituted condensed tricyclic amine compounds and uses thereof as ras inhibitors
WO2025006967A1 (en) 2023-06-30 2025-01-02 Bristol-Myers Squibb Company Kras inhibitors
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
KR20260096846A (ko) 2023-10-20 2026-06-24 머크 샤프 앤드 돔 엘엘씨 Kras 단백질의 소분자 억제제
AU2024404270A1 (en) * 2023-12-19 2026-07-23 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Fused tricyclic compound and medical use thereof
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
TW202608896A (zh) * 2024-04-30 2026-03-01 大陸商和記黃埔醫藥（上海）有限公司 抗體藥物偶聯物及其用途
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026035945A1 (en) 2024-08-07 2026-02-12 Tesseract Medicines Us, Llc Covalent-induced drug conjugates targeting kras and comprising a topoisomerase payload
TW202615038A (zh) 2024-08-07 2026-04-16 美商太斯萊特醫藥美國有限責任公司 包含拓樸異構酶有效載荷之靶向ｋｒａｓ之共價誘導之藥物結合物
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026064520A1 (en) 2024-09-19 2026-03-26 Tesseract Medicines Us, Llc Covalent-induced drug conjugates targeting kras and comprising a tubulin inhibitor payload
WO2026064527A1 (en) 2024-09-19 2026-03-26 Tesseract Medicines Us, Llc Kras-targeting covalent-induced drug conjugates comprising a tubulin inhibitor payload
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors
CN119874616B (zh) * 2025-03-28 2025-05-30 四川美域高生物医药科技有限公司 一种有机中间体及其制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020519589A (ja) * 2017-05-11 2020-07-02 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ Ｇ１２ｃ変異型ｒａｓタンパク質を阻害するヘテロアリール化合物
WO2020221239A1 (zh) * 2019-04-28 2020-11-05 劲方医药科技(上海)有限公司 氧杂氮杂喹唑啉-7(8h)-酮类化合物，其制法与医药上的用途
CN113980032A (zh) * 2020-07-27 2022-01-28 江苏恒瑞医药股份有限公司 稠合四环类衍生物、其制备方法及其在医药上的应用
JP2024534610A (ja) * 2021-09-27 2024-09-20 ジャコバイオ ファーマスーティカルズ カンパニー リミテッド 多環式縮合環誘導体およびその利用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
SI2242771T1 (sl) 2007-12-14 2013-09-30 Bristol-Myers Squibb Company Vezane molekule k humanemu ox40 receptorju
SA112330278B1 (ar) 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
EP2760857A1 (en) 2011-09-27 2014-08-06 F.Hoffmann-La Roche Ag Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
EP2780039B9 (en) 2011-11-17 2018-04-18 Pfizer Inc Cytotoxic peptides and antibody drug conjugates thereof
MX2016017393A (es) 2014-07-01 2017-09-05 Pfizer Diacuerpos heterodimericos biespecificos y sus usos.
HUE057285T2 (hu) 2015-04-13 2022-04-28 Pfizer Terápiás ellenanyagok és alkalmazásaik
WO2017175156A1 (en) 2016-04-07 2017-10-12 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
SG10201900628RA (en) 2016-04-07 2019-02-27 Glaxosmithkline Ip Dev Ltd Heterocyclic amides useful as protein modulators
US11589667B2 (en) 2016-11-16 2023-02-28 Wink Robotics Deformable end effectors for cosmetic robotics
CN111148762A (zh) 2017-05-31 2020-05-12 斯特库伯株式会社 免疫特异性结合至btn1a1的抗体和分子及其治疗性用途
JP7234142B2 (ja) 2017-06-02 2023-03-07 ファイザー・インク Ｆｌｔ３に特異的な抗体およびその使用
MA49772A (fr) 2017-08-04 2021-04-21 Merck Sharp & Dohme Agonistes benzo[b]thiophène de sting pour le traitement du cancer
CN114615981B (zh) 2019-08-29 2024-04-12 米拉蒂治疗股份有限公司 Kras g12d抑制剂
EP4262807A4 (en) * 2020-12-15 2025-04-23 Mirati Therapeutics, Inc. Azachinazoline pan-KRAS inhibitors
CN117083281A (zh) * 2021-03-24 2023-11-17 南京明德新药研发有限公司 嘧啶并杂环类化合物及其应用
TW202315626A (zh) * 2021-08-31 2023-04-16 大陸商勁方醫藥科技(上海)有限公司 嘧啶并環類化合物及其製法和用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020519589A (ja) * 2017-05-11 2020-07-02 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ Ｇ１２ｃ変異型ｒａｓタンパク質を阻害するヘテロアリール化合物
WO2020221239A1 (zh) * 2019-04-28 2020-11-05 劲方医药科技(上海)有限公司 氧杂氮杂喹唑啉-7(8h)-酮类化合物，其制法与医药上的用途
CN113980032A (zh) * 2020-07-27 2022-01-28 江苏恒瑞医药股份有限公司 稠合四环类衍生物、其制备方法及其在医药上的应用
JP2024534610A (ja) * 2021-09-27 2024-09-20 ジャコバイオ ファーマスーティカルズ カンパニー リミテッド 多環式縮合環誘導体およびその利用

Also Published As

Publication number Publication date
TW202409047A (zh) 2024-03-01
CA3261000A1 (en) 2024-01-11
AU2023302139A1 (en) 2024-12-19
TWI869913B (zh) 2025-01-11
MX2024015001A (es) 2025-01-09
CO2024016875A2 (es) 2024-12-19
PY2352053A (es) 2025-03-06
TW202513571A (zh) 2025-04-01
KR20250029954A (ko) 2025-03-05
EP4551296A1 (en) 2025-05-14
CL2024003699A1 (es) 2025-04-11
IL317957A (en) 2025-02-01
MA71388A (fr) 2025-04-30
CR20240556A (es) 2025-01-29
CN119585286A (zh) 2025-03-07
DOP2024000275A (es) 2025-01-31
PE20250259A1 (es) 2025-01-29
WO2024009191A1 (en) 2024-01-11

Similar Documents

Publication Publication Date Title
TWI869913B (zh) 吡啶并[4,3-d]嘧啶化合物
US12281127B2 (en) Pyrido[4,3-d]pyrimidine compounds
WO2024218686A1 (en) Pyrido[4,3-d]pyrimidine compounds
JP2025100453A (ja) ピリド［４，３－ｄ］ピリミジン化合物
WO2024213979A1 (en) Pyrido[4,3-d]pyrimidine compounds
KR20250100539A (ko) 피리도[4,3-d]피리미딘 화합물
AU2020200407B2 (en) Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof
EP4301363A1 (en) Quinazoline amine derivatives as kras inhibitors
TWI755788B (zh) 類鐸受體促效劑
WO2024105563A1 (en) Substituted bicyclic pyridone derivatives
JP2019508368A (ja) コルチスタチン類縁体及びその使用
WO2024003773A1 (en) 2,7-naphthyridine compounds as mastl inhibitors
RU2857665C2 (ru) Соединения пиридо[4,3-d]пиримидина
US20190062340A1 (en) Cortistatin analogs
HK40117290A (en) Pyrido[4,3-d]pyrimidine compounds
US20240140947A1 (en) Compound for the treatment of cancer
JP2026059772A (ja) ピリド［４，３－ｄ］ピリミジン化合物
WO2025094035A1 (en) Toll-like receptor agonists and conjugates thereof
KR20260044145A (ko) 피리도[4,3-d]피리미딘 화합물
HK40128596A (zh) 吡啶并[4，3-d]嘧啶化合物
WO2024074977A1 (en) Substituted 1 h-pyrazolo-pyridine and-pyrimidine compounds
CA3130469A1 (en) Tricyclic degraders of ikaros and aiolos

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250925

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250925

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20250925

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251104

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260324

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260601